252 related articles for article (PubMed ID: 25124653)
1. Oncometabolites-driven tumorigenesis: From genetics to targeted therapy.
Morin A; Letouzé E; Gimenez-Roqueplo AP; Favier J
Int J Cancer; 2014 Nov; 135(10):2237-48. PubMed ID: 25124653
[TBL] [Abstract][Full Text] [Related]
2. Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.
Menendez JA; Alarcón T; Joven J
Cell Cycle; 2014; 13(5):699-709. PubMed ID: 24526120
[TBL] [Abstract][Full Text] [Related]
3. Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH): three players for one phenotype in cancer?
Laurenti G; Tennant DA
Biochem Soc Trans; 2016 Aug; 44(4):1111-6. PubMed ID: 27528759
[TBL] [Abstract][Full Text] [Related]
4. A systems approach to predict oncometabolites via context-specific genome-scale metabolic networks.
Nam H; Campodonico M; Bordbar A; Hyduke DR; Kim S; Zielinski DC; Palsson BO
PLoS Comput Biol; 2014 Sep; 10(9):e1003837. PubMed ID: 25232952
[TBL] [Abstract][Full Text] [Related]
5. Oncometabolites: tailoring our genes.
Nowicki S; Gottlieb E
FEBS J; 2015 Aug; 282(15):2796-805. PubMed ID: 25864878
[TBL] [Abstract][Full Text] [Related]
6. Rare insights into cancer biology.
Adam J; Yang M; Soga T; Pollard PJ
Oncogene; 2014 May; 33(20):2547-56. PubMed ID: 23812428
[TBL] [Abstract][Full Text] [Related]
7. The role of mutation of metabolism-related genes in genomic hypermethylation.
Waterfall JJ; Killian JK; Meltzer PS
Biochem Biophys Res Commun; 2014 Dec; 455(1-2):16-23. PubMed ID: 25111818
[TBL] [Abstract][Full Text] [Related]
8. Metabolic reprogramming and epithelial-to-mesenchymal transition in cancer.
Sciacovelli M; Frezza C
FEBS J; 2017 Oct; 284(19):3132-3144. PubMed ID: 28444969
[TBL] [Abstract][Full Text] [Related]
9. From Metabolism to Genetics and Vice Versa: The Rising Role of Oncometabolites in Cancer Development and Therapy.
Di Gregorio E; Miolo G; Saorin A; Steffan A; Corona G
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070384
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.
Gaal J; Burnichon N; Korpershoek E; Roncelin I; Bertherat J; Plouin PF; de Krijger RR; Gimenez-Roqueplo AP; Dinjens WN
J Clin Endocrinol Metab; 2010 Mar; 95(3):1274-8. PubMed ID: 19915015
[TBL] [Abstract][Full Text] [Related]
11. Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?
Bayley JP; Devilee P
Curr Opin Genet Dev; 2010 Jun; 20(3):324-9. PubMed ID: 20304625
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations.
Pollard PJ; Brière JJ; Alam NA; Barwell J; Barclay E; Wortham NC; Hunt T; Mitchell M; Olpin S; Moat SJ; Hargreaves IP; Heales SJ; Chung YL; Griffiths JR; Dalgleish A; McGrath JA; Gleeson MJ; Hodgson SV; Poulsom R; Rustin P; Tomlinson IP
Hum Mol Genet; 2005 Aug; 14(15):2231-9. PubMed ID: 15987702
[TBL] [Abstract][Full Text] [Related]
13. Oncometabolites: linking altered metabolism with cancer.
Yang M; Soga T; Pollard PJ
J Clin Invest; 2013 Sep; 123(9):3652-8. PubMed ID: 23999438
[TBL] [Abstract][Full Text] [Related]
14. Metabolic alteration in tumorigenesis.
Yang H; Xiong Y; Guan K
Sci China Life Sci; 2013 Dec; 56(12):1067-75. PubMed ID: 24114443
[TBL] [Abstract][Full Text] [Related]
15. Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases.
Kaelin WG
Cold Spring Harb Symp Quant Biol; 2011; 76():335-45. PubMed ID: 22089927
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas.
Castro-Vega LJ; Buffet A; De Cubas AA; Cascón A; Menara M; Khalifa E; Amar L; Azriel S; Bourdeau I; Chabre O; Currás-Freixes M; Franco-Vidal V; Guillaud-Bataille M; Simian C; Morin A; Letón R; Gómez-Graña A; Pollard PJ; Rustin P; Robledo M; Favier J; Gimenez-Roqueplo AP
Hum Mol Genet; 2014 May; 23(9):2440-6. PubMed ID: 24334767
[TBL] [Abstract][Full Text] [Related]
17. Genetically-defined metabolic reprogramming in cancer.
Mullen AR; DeBerardinis RJ
Trends Endocrinol Metab; 2012 Nov; 23(11):552-9. PubMed ID: 22858391
[TBL] [Abstract][Full Text] [Related]
18. Oncometabolites in cancer aggressiveness and tumour repopulation.
Dando I; Pozza ED; Ambrosini G; Torrens-Mas M; Butera G; Mullappilly N; Pacchiana R; Palmieri M; Donadelli M
Biol Rev Camb Philos Soc; 2019 Aug; 94(4):1530-1546. PubMed ID: 30972955
[TBL] [Abstract][Full Text] [Related]
19. Succinate dehydrogenase-deficient tumors: diagnostic advances and clinical implications.
Barletta JA; Hornick JL
Adv Anat Pathol; 2012 Jul; 19(4):193-203. PubMed ID: 22692282
[TBL] [Abstract][Full Text] [Related]
20. Fumarate hydratase in cancer: A multifaceted tumour suppressor.
Schmidt C; Sciacovelli M; Frezza C
Semin Cell Dev Biol; 2020 Feb; 98():15-25. PubMed ID: 31085323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
